"We have a cash balance of close to Rs 1,500 crore. A majority of this balance can be used for acquisitions as our annual working capital requirement is only Rs 25-30 crore. I will not rule out a buyout of companies to expand our domestic business," said Mernosh Kapadia, senior executive director, GSK India. It is speculated that GlaxoSmithKline Plc is in talks to acquire leading Indian drug major Piramal Healthcare, in a deal valued over $1.5 billion.
Severe price cuts help multinationals ramp up growth, gain market share.
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.
The NPPA letter was issued to GSK on Wednesday.
IT sector's trading multiples hit post-Lehman lows, providing good entry points.
India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.
The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.
GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.
Glenmark Generics Inc has settled the litigation pending between the company and GSK over patent actions concerning atovaquone and proguanil hydrochloride 250mg/100mg tablets, the generic version of GSK's Malarone tablets, Glenmark Pharma said.
The markets opened in green tracking its Asian peers
Pharma companies gear up for the 'new normal' as they train and align their sales forces for a paradigm shift. GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family.
The Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per cent shares in existing Indian subsidiary company of GSK Group.
Pharma major GlaxoSmithKline and software giant Tata Consultancy Services on Tuesday signed a 'multi-year, multi-million dollar' contract to set up a global drug development support centre in Mumbai.
In separate statements, the two companies said they will combine Novartis' over-the-counter division with GSK's consumer business, creating a new world-leading consumer healthcare business with $10 billion in annual sales.
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
Sensex rises, Nifty holds 8,900; FMCG, Pharma shares lead.
The top 300 pharmaceutical brands in the country will now bear a quick response (QR) code on their packaging to rein in spurious drugs and ensure better traceability.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
The list of guests included celebrities from across the globe, politicians, the who's who of Hindi and south Indian cinema world and almost all the top cricketers of the country.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Some investment bankers expect the Indian currency to touch 60-65 by the end of the year
For the first time since 2001, promoter stake in BSE 500 decisively below 50%
GSK India, which has a turnover of Rs 1,751 crore (Rs 17.51 billion) and launched a cervical cancer drug, Cervarix, and breast cancer drug, Tykerb, last year, plans to launch Promacta, the first oral medication to increase platelet production for people with serious blood disorder, from its parent stable during the current year. Promacta is a relatively new drug, for which approval was given by the US Food and Drug Administration in November last year.
Dilip Shanghvi founded Sun Pharma in 1983.
A large number of American companies like Google, Uber and IBM are offering their resources to help India successfully fight the battle against the deadly coronavirus pandemic.
Pharma major Ranbaxy Laboratories on Thursday said it has scored a legal victory with a United States court ruling that its Cefuroxime Exetil product does not infringe upon the patent rights of GlaxoSmithKline.
Pharma major GlaxoSmithKline Pharmaceuticals Ltd has sold its Worli plot for Rs 107.6 crore (Rs 1.08 billion) to I-Ven Realty Ltd, a joint venture between ICICI Venture Funds Management Company Ltd and Oberoi Constructions.
The British pharma and consumer products maker had announced the open offer in November last year to raise its stake in its subsidiary to 75 per cent from 43.16 per cent at present.
Dr Reddy's has reached an out-of-court settlement to launch the Glaxo-patented Imitrex, a migraine drug that had annual sales of $878 million as of March 31, 2006, in the US. Experts estimate Dr Reddy's may not get more than $8-$15 million sales in 2009 since majority of sales revenue has to be given to GSK, for allowing the launch the authorised generic version.
Drug major Ranbaxy Laboratories could suffer a potential revenue loss to the tune of Rs 300 crore (Rs 3 billion) due to delay in receiving approval from the US Food and Drug Administration (FDA) for generic version of GSK's anti-migraine medicine Imitrex, according to analysts.
Some big ones hoard cash unduly and others borrow to keep up payments to shareholders
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances